生物试剂
>
生化试剂
>
信号通路
> NSC745885
加入收藏 取消收藏

NSC745885  ≥98%

促销价¥{{model.attbuying.price}}

市场价¥0.00

累计销量0 累计评价0 人评论

别称 {{model.alias}}
中文名称 {{model.name}}
英文名称 {{model.enname}}
品牌 {{model.brand}}
CAS {{model.cas}}
分子式
分子量 {{model.molecularweight}}
MDL {{model.mdl}}
货号 {{model.procode}}
数量

+ -

件 库存{{model.attbuying.number}}件
立即购买 加入购物车 下载说明书

看了又看
包装规格：5mg 10mg in glass bottle
产品描述：基本信息 产品编号：N10502 产品名称：NSC745885 CAS: 4219-52-7   储存条件 粉末 -20℃ 四年     分子式： C14H6N2O2S 溶于液体 -80℃ 六个月 分子量 266.27 -20℃ 一个月 化学名：      Solubility (25°C)   体外 DMSO   Ethanol   Water   体内（现配现用）     ＜1mg/ml表示微溶或不溶。 普西唐提供的所有化合物浓度为内部测试所得，实际溶液度可能与公布值有所偏差，属于正常的批间细微差异现象。 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；⼀旦配成溶液，请分装保存，避免反复冻融造成的产品失效。   生物活性 产品描述 一种有效的抗肿瘤 (anti-tumor) 试剂，对多种癌细胞株有选择性毒性，但对正常细胞没有毒性。 靶点/IC50 EZH2 体外研究 NSC745885 (0.5-4μM;24,48 or 72 hours) has a growth inhibitory or death-promoting effect on the SAS cells,it significantly decreases the densities of cultured cells when compared with untreated cells. The IC50 of NSC745885 is 0.85μM after 72 hours’treatment. NSC745885 (0.5-4μM; 24 hours) increases annexin V positive cells in a dose-dependent manner, and the differences appears as a dose-dependent manner. NSC745885 (0.5-2μM; 24 or 48 hours) decreases XIAP protein levels and increases protein levels both as a dose-dependent manner in SAS cells.Cell Viability Assay Cell Line: SAS cells is obtained from a poorly differentiated human squamous cell carcinoma Concentration: 0.5μM,1μM,1.5μM,2μM,4μM Incubation Time: 24,48,or 72 hours Result: Decreases SAS cells growth as a time and dose-dependent manner. Apoptosis Analysis Cell Line: SAS cells is obtained from a poorly differentiated human squamous cell carcinoma Concentration: 0.5μM,1μM,1.5μM,2μM,4μM Incubation Time: 24 hours Result:   Decreases SAS cells growth as a time and dose-dependent manner. Western Blot Analysis Cell Line: SAS cells is obtained from a poorly differentiated human squamous cell carcinoma Concentration: 0.5μM,1μM,1.5μM,2μM Incubation Time: 24 or 48 hours Result:   Increased cleaved caspase-3 expression and decreased XIAP expression. 体内研究 NSC745885 (intraperitoneal injection; 2mg/kg; once daily; 10 days) treatment significantly reduces tumor size when compared with the vehicle control, and exhibits a higher safety than doxorubicin. Animal Model: Eight-week-old NOD/SCID (NOD.CB17 Prkdcscid/J) mice Dosage: 2mg/kg Administration: Intraperitoneal injection;2mg/kg;once daily;10 days Result: Inhibited engrafted tumors growth in vivo.
保存条件：-20℃

猜你喜欢